ENXTPA:ALMED

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Medicrea International

Executive Summary

Medicrea International SA designs, manufactures, and distributes spinal implants in France and internationally.


Snowflake Analysis

Worrying balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Medicrea International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALMED's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.1%

ALMED

-11.5%

FR Medical Equipment

8.7%

FR Market


1 Year Return

59.9%

ALMED

42.8%

FR Medical Equipment

-2.4%

FR Market

Return vs Industry: ALMED exceeded the French Medical Equipment industry which returned 47.9% over the past year.

Return vs Market: ALMED exceeded the French Market which returned -4.4% over the past year.


Shareholder returns

ALMEDIndustryMarket
7 Day-1.1%-11.5%8.7%
30 Day44.6%-1.9%15.9%
90 Day-0.4%35.6%1.3%
1 Year59.9%59.9%42.8%42.8%-0.7%-2.4%
3 Year-14.5%-14.5%43.9%42.1%11.2%2.2%
5 Year-36.5%-36.5%144.9%139.2%31.1%14.3%

Price Volatility Vs. Market

How volatile is Medicrea International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Medicrea International undervalued compared to its fair value and its price relative to the market?

10.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALMED's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALMED's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALMED is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: ALMED is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALMED's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALMED is overvalued based on its PB Ratio (10.1x) compared to the FR Medical Equipment industry average (3x).


Next Steps

Future Growth

How is Medicrea International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medicrea International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Medicrea International performed over the past 5 years?

-35.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALMED is currently unprofitable.

Growing Profit Margin: ALMED is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALMED is unprofitable, and losses have increased over the past 5 years at a rate of -35.2% per year.

Accelerating Growth: Unable to compare ALMED's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALMED is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-2%).


Return on Equity

High ROE: ALMED has a negative Return on Equity (-208.04%), as it is currently unprofitable.


Next Steps

Financial Health

How is Medicrea International's financial position?


Financial Position Analysis

Short Term Liabilities: ALMED's short term assets (€21.5M) exceed its short term liabilities (€16.6M).

Long Term Liabilities: ALMED's short term assets (€21.5M) do not cover its long term liabilities (€45.9M).


Debt to Equity History and Analysis

Debt Level: ALMED's debt to equity ratio (670.3%) is considered high.

Reducing Debt: ALMED's debt to equity ratio has increased from 51% to 670.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ALMED has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALMED has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Medicrea International's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALMED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALMED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALMED's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALMED's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALMED's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Denys Sournac (55yo)

no data

Tenure

€308,000

Compensation

Mr. Denys Sournac serves as the Owner, President and Chief Executive Officer at Orsco Laboratoire Vétérinaire, SAS. He also serves as the Chairman of Orsco Laboratoire Vétérinaire, SAS. Mr. Sournac has bee ...


CEO Compensation Analysis

Compensation vs Market: Denys's total compensation ($USD345.91K) is about average for companies of similar size in the French market ($USD324.57K).

Compensation vs Earnings: Denys's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Denys Sournac
Co-Founderno data€308.00k3.11% 2.9m
Fabrice Kilfiger
Chief Financial Officerno data€208.62k0.030% 28.2k
David Ryan
Chief Operating Officer1.42yrs€207.50k0.12% 113.5k
Jean Caffiero
Co-Founder18.25yrs€7.00k1.09% 1.0m
Pierre-Laurent Ravis
Chief Information Officerno datano datano data
Thomas Mosnier
Chief Scientific Officerno datano datano data
Nadège Bourdois
Vice President of Human Resources & Legalno datano datano data
Richard Kienzle
Chief Commercial & Business Development Officer and Director3.83yrsno data0.52% 483.5k
Joseph Walland
Chief Executive Officer of Medicrea USA2.67yrsno datano data

2.7yrs

Average Tenure

55yo

Average Age

Experienced Management: ALMED's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Denys Sournac
Co-Founderno data€308.00k3.11% 2.9m
Jean Caffiero
Co-Founder18.25yrs€7.00k1.09% 1.0m
Richard Kienzle
Chief Commercial & Business Development Officer and Director3.83yrsno data0.52% 483.5k
M. Ory
Independent Director13yrs€4.00k0.55% 510.7k
Patrick Bertrand
Director18.25yrs€4.00k0.58% 535.6k
Marc Recton
Independent Director17yrs€4.00k0.39% 361.7k
Christophe Bonnet
Independent Director18.25yrs€4.00k0.26% 245.0k
Jean Moreno
Director18.25yrs€4.00k0.11% 103.4k
Pierre Olivier
Director2.08yrsno data0.14% 126.9k
Pierre Burel
Director18.25yrsno data0.98% 914.6k

18.3yrs

Average Tenure

56.5yo

Average Age

Experienced Board: ALMED's board of directors are seasoned and experienced ( 18.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.2%.


Top Shareholders

Company Information

Medicrea International SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medicrea International SA
  • Ticker: ALMED
  • Exchange: ENXTPA
  • Founded: 1990
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €93.142m
  • Shares outstanding: 19.82m
  • Website: https://www.medicrea.com

Number of Employees


Location

  • Medicrea International SA
  • 5389, route de Strasbourg
  • Rillieux-la-Pape
  • Rhône-Alpes
  • 69140
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALMEDENXTPA (Euronext Paris)YesOrdinary SharesFREURJun 2006
MRNT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2006
0A3CLSE (London Stock Exchange)YesOrdinary SharesGBEURJun 2006
MRNT.YOTCPK (Pink Sheets LLC)SPONSORED ADSUSUSDAug 2018

Biography

Medicrea International SA designs, manufactures, and distributes spinal implants in France and internationally. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; LigaPASS, a band connector for posterior thoracolumbar fixation; PASS TULIP, a top loading system; PASS OCT, an occipito-cervico-thoracic fixation system; PASS MIS, a posterior anchoring system; and PASS ANT, a polyaxial low profile thoraco-lumbar system for anterior approach, as well as various implants for the cervical spine, including C-JAWS, an anterior cervical spinal fixation system; IMPIX C, a sterile PEEK Optima cervical interbody device; IMPIX-C+, a sterile PEEK Optima cervical interbody device that is prefilled with bone substitute; and IMPIX-MANTA, a sterile PEEK Optima cervical interbody device that is preassembled on holder and delivers with a disposable instrumentation kit. Its implants for cervical spine also include IMPIX-MANTA +, a sterile PEEK Optima cervical interbody device, which is prefilled with bone substitutes; and preassembled on holder/impactor and delivered with disposable instrumentation kit; and GRANVIA-C, a MRI compatible ceramic cervical disc. It offers implants for the thoracic and lumbar spine, such as IMPIX-L, a sterile PEEK Optima lumbar interbody device for posterior approach; IMPIX-TLIF, a sterile PEEK Optima lumbar interbody device for transforaminal approach; IMPIX-ALIF, a sterile PEEK Optima lumbar interbody device for anterior approach; STABOLT, an anatomically-shaped anterior plate; OSMOSYS, a macro porous bone substitute; IMPIX-DLIF and IMPIX-DLIF SLIM sterile PEEK Optima lumbar interbody devices for direct or oblique lateral approach; and IMPIX-S, an oblique TLIF interbody device. Its implants are designed to treat scoliosis, degenerative diseases, malformations, trauma, and tumors; and used in various traditional and surgical procedures. The company was founded in 1990 and is headquartered in Rillieux-la-Pape, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/04 21:01
End of Day Share Price2020/06/04 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.